AzTrials
AzTrials

Major DepressionRECORDNCT03492203

Remote Cognitive Remediation for Depression

A study testing Active Cognitive Remediation, Online computer exercises and Strategy monitoring in people with Major Depression, run by Queen's University at 1 site in Canada.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Major depressive disorder is the number one cause of disability worldwide. Evidence regarding the effectiveness of various treatments for patients with severe depression is still lacking. Although many patients achieve treatment response, only a minority of patients achieve full remission and even fewer sustain it. Read more about this study

Who is it for?
Ages 18 to 60 years
Conditions the study is for
Major Depression
What is being tested?
Active Cognitive Remediation, Online computer exercises and Strategy monitoring
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
75 participants
Where
1 siteCanada
Study dates
Dec 2016to Jan 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 60 years
  • All sexes
  • No healthy volunteers
  • Adult

Inclusion Criteria: Participants must have a primary diagnosis of Major Depressive Disorder

Exclusion Criteria: Medical conditions that affect central nervous system functioning, substance abuse within the past three months (assessed with the SCID-V), and sensory or perceptual conditions that affect validity of testing.

Trial locations and contacts

1 site in 1 country.

Tammy L Vanrooy, BA Hons Law contact

613 533 6000 ext. 78478

tammy.vanrooy@queensu.ca

Canada1 site, 1 recruiting
  • Queen's University

    Kingston, Ontario, K7L3N6

    Tammy Vanrooy, BA Hons Law, 613-533-6000 ext. 78478, tammy.vanrooy@queensu.ca

    Christopher Bowie, PhD, CPsych

    Recruiting

Other trials in Canada

About this study

Major depressive disorder is the number one cause of disability worldwide. Evidence regarding the effectiveness of various treatments for patients with severe depression is still lacking. Although many patients achieve treatment response, only a minority of patients achieve full remission and even fewer sustain it. In fact, within one month 10% will be re-hospitalized and the rate climbs to 30% within a year. Further, remission from depressive symptoms is a surprisingly poor predictor of recovery of community functioning following discharge. It is clear that the traditional focus on diagnostic symptoms is insufficient for promoting a full return to everyday functioning. The present aim is to examine the efficacy and effectiveness of treating neurocognition, a symptom that explains persistent deficits in community functioning for those with depression. The study design that maps on to the contemporary clinical setting, in order to reflect the changing landscape of inpatient and community treatment.

Read the detailed description

Cognitive impairment in depression has emerged as one of the most robust predictors of sustained impairment in everyday functioning. Significant deficits in attention, memory and executive function are widespread and remain even after effective treatment of primary mood symptoms. Relevant to the investigators aims, severity of cognitive impairments has been linked to more severe episodes and higher rates of relapse. Cognitive Remediation (CR) is a psychological treatment developed and tested in research settings, where techniques that train the brain to process information more efficiently result in improvements in cognition and in community functioning. Contemporary CR relies on three pillars of treatment: Drill and Practice, Strategic Monitoring, and Bridging of Cognitive Skills to Everyday Life. CR treatment produces robust effects in depression, with some evidence for transfer to reduced depressive symptoms. However, each of the three pillars is typically done within a group therapy context, with two or more meetings per week, presenting a challenge to both modern health care models and the symptoms of depression that would be barriers to attendance (low motivation, social anxiety, lack of energy). The investigators have recently developed a Remote Cognitive Remediation program that overcomes these obstacles with novel components of CR to allow for delivery of treatment remotely. These techniques include the use of online exercises for an increased dose, and the delivery of recorded visual examples of bridging strategies. Efficacy (cognitive improvement) and effectiveness (improved community functioning, reduced time to relapse) will be compared to a placebo control group in this 12-week randomized controlled trial with 6-month follow-up assessments.

This project has the potential to address a significant gap in the treatment of depression and to modify an established treatment to fit into the changing demands of the health care system.

Aim 1: To examine whether cognitive remediation, delivered at home over the Internet, is efficacious in improving cognition in symptomatic individuals with recurrent MDD.

Aim 2: To examine the effectiveness of remote cognitive remediation for improving community functioning.

Aim 3: To examine the baseline and dynamic predictors and mediators of change in functioning for patients with MDD who receive cognitive remediation.

Exploratory Aim: To examine whether cognitive remediation affects rates of response, remission, and relapse.

Hypothesis 1: Remote cognitive remediation will improve neurocognitive functioning at post-treatment and these improvements will persist for 24 weeks.

Hypothesis 2a: Remote cognitive remediation will improve functional capacity at post-treatment and these improvements will persist for 24 weeks.

Hypothesis 2b: Remote cognitive remediation will improve functioning in the community 24 weeks post-treatment.

Hypothesis 3: Improvements in cognitive functioning will predict improvements in functional capacity and functional behaviours post-treatment and 24 weeks later, controlling for depressive symptoms at baseline and change in depressive symptoms. Social cognitive functioning and social anxiety will mediate the degree to which cognitive and functional capacity relate to real world behavior change.

Exploratory Hypotheses:

A.Remote cognitive remediation will increase response and remission rates, and reduce rates of relapse over a 24 week period.

B.12 weeks of CR will demonstrate equivalency in treatment effects to 24 weeks of CR

Participants will be randomized to one of three groups. Two groups will receive active cognitive remediation, with one terminating sessions after 12 weeks (the standard length of time in the literature) and one continuing for a total of 24 weeks of treatment. The third group will receive a comparison training group where they will login to the same training environment but the difficulty level of the working memory load will not progress over time but the tasks will be longer (referred to in the consent as 'focusing your attention for longer periods of time). In previous work, the investigators have found participants to be equally compliant with these groups and for specific changes in memory or attention depending on the group to which they are assigned. Participants will be tested at baseline, 12 weeks (post-intervention, intermediate intervention, or sham, respectively), and at 6 months post-intervention. This design will allow the investigators to test a 2:1 ratio of participants in active memory training versus comparison on the baseline to 12 week assessments and a 1:1:1 comparison for the short-term treatment, long-term treatment, and comparison condition.

Assessments:

Standardized testing will be performed at baseline and/or screening, during clinic visits, and immediately following 12 weeks of intervention. The investigators will also perform a durability assessment at endpoint (end of study participation or at time of dropout) and at 6 months post-treatment to examine the persistence and transfer of effects.

Neurocognition will be assessed with the CNS Vitals system (CNSVS).

Social Cognition will be examined as a potential mediator of changes in cognition and functional capacity to functional behaviour.

The investigators will use the Bell-Lysaker Emotion Recognition Test, which they have previously found to be sensitive to impairment and cognitive treatment in depression.

Functional capacity will be assessed with the Virtual Reality Functional Capacity Assessment, which is a computerized performance based assessment of independent living skills such as planning and shopping.

The 4-item Perceived Competence Scale will assess self-ratings of ability on the measures prior to and after testing.

Functional Behaviour will be assessed with the the World Health Organization Quality of Life Assessment (WHOQoL-BREF).

The Sheehan Disability Scale (SDS) will be used to assess subjective quality of life. The Lam Employment Absence and Productivity Scale (LEAPS) will be used to measure occupational functioning.

Symptoms of depression will be assessed with Montgomery-Asberg Depression Rating Scale MADRS, a gold standard interview-based assessment of 10 items common to MDD.

Other measures that are used include: The Self-Report of Cognitive Lifestyle, The Need for Cognition Scale, The Cognitive Approach Scale, and The Cognitive Failures Questionnaire.

Intervention:

The study will include the foundational Pillars of CR, but modified for this study in a structure that fits contemporary health care systems and with the intention of extending cognitive effects to improved community functioning. The novel components of CR in this study will be the delivery of treatment remotely, the use of online exercises for an increased dose, and the delivery of recorded visual examples of strategic monitoring and bridging strategies.

Pillar I: Cognitive Activation. In the treatment, the use of online exercises allow for a steadier dose of treatment compared to week to week in-person meetings, essential for motivation and learning. There are 30 unique cognitive exercises in the program (sbtpro.com). The investigators will prescribe 24 exercises in the domains most commonly impaired in MDD: six targeting executive functions, ten targeting memory, and eight targeting attention and working memory. The specific activities are prescribed in a fixed, systematic order, such that the participants have a schedule of exercises that address several different cognitive domains each week and return to exercises in subsequent weeks. Parameters are automatically adjusted based on participant performance across 30 difficulty levels. Participants are prescribed two 20-minute sessions per day, five days per week, for the duration of the study. Participants who do not complete tasks for three consecutive days will receive reminder calls from a therapist to address technical or motivational issues.

Pillar II: Strategy Monitoring, Development, and Pruning. Therapists communicate with participants in asynchronous private and group forums, where specific responses to questions prime flexible strategy formation, monitoring of strategies, and bridging to real world functioning. Participants use logs to track their own strategies and upload this information to the forum for therapist feedback. The purpose of the therapist responses is to reinforce the development of multiple strategies and help supplement or reshape those that are concrete, based on a predetermined list of strategies developed for each of the computer exercises.

Pillar III: Bridging. The online forum will have illustrations for bridging cognitive abilities and problem solving strategies related to each game to experiences in the real world. An at home workbook will also be used to facilitate active application of skills in various domains (e.g., work, socialization, recreation, household maintenance).

Comparison Control Group: Comparison cognitive remediation treatment procedures include the same stimuli that are presented in the active treatment condition, but the parameter adjustments change without increasing cognitive demand.

Those who consent will be assigned to the CR or Comparison treatment conditions on a 2:1 basis, based on a computerized random number generator. Allocation to active treatment at 2:1 has advantages related to within group analysis to predict outcomes, trial costs, expected dropouts, and patient acceptability, and does not reduce power. Participants will meet with a study therapist for an orientation to the computer tasks and goal setting in a one-hour training session. Those who experience difficulty understanding or utilizing the program will receive additional training, though this contact will continue to be only computer skill training rather than therapeutic. The study coordinator and assistant will remain available throughout the study for asynchronous responses to email and live telephone support related to usage issues. The goal setting session follows the investigator's standard protocol, which is a collaborative discussion to identify real world functional goals, discuss how the patient's individual cognitive profile links with those goals, and demonstrate how the treatment techniques are related to their profile and everyday functional goals. Ph.D.-level psychology students or psychologists from the PI's laboratory will be available on an asynchronous nature to respond to online Strategic Monitoring and Bridging forum questions and to moderate comments.

Being tested
Active Cognitive Remediation, Cognitive Remediation Control, Online computer exercises, Strategy monitoring, Bridging strategies
Keywords
Cognitive Remediation, Neurocognition, Severe mental illness, Remote treatment
Medical subject headings
Depressive Disorder, Major, Mental Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Active Cognitive RemediationBehavioural

    Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life. The novel components of CR in this study will be the delivery of treatment remotely.

  • Cognitive Remediation ControlBehavioural

    The investigators have developed a 'comparison' cognitive remediation treatment in collaboration with the same company that produced the cognitive exercises. These procedures include the same stimuli but are adjusted without increasing cognitive load.

  • Online computer exercisesBehavioural

    There are 30 unique cognitive exercises in the program (sbtpro.com). The investigators will prescribe 24 exercises in the domains most commonly impaired in MDD: six targeting executive functions, ten targeting memory, and eight targeting attention and working memory. The specific activities are prescribed in a fixed, systematic order, such that the participants have a schedule of exercises that address several different cognitive domains each week and return to exercises in subsequent weeks. Parameters are automatically adjusted based on participant performance across 30 difficulty levels. Participants are prescribed two 20-minute sessions per day, five days per week, for the duration of the study.

  • Strategy monitoringBehavioural

    Therapists communicate with participants in asynchronous private and group forums, where specific responses to questions prime flexible strategy formation, monitoring of strategies, and bridging to real world functioning. Participants use logs to track their own strategies and upload this information to the forum for therapist feedback. The purpose of the therapist responses is to reinforce the development of multiple strategies and help supplement or reshape those that are concrete, based on a predetermined list of strategies developed for each of the computer exercises.

  • Bridging strategiesBehavioural

    The online forum will have illustrations for bridging cognitive abilities and problem solving strategies related to each game to experiences in the real world. An at home workbook will also be used to facilitate active application of skills in various domains (e.g., work, socialization, recreation, household maintenance).

Study groups in NCT03492203
Study groupRoleWhat they receive
Active Cognitive Remediation -Long-termExperimentalParticipants in the long-term treatment will receive 24 weeks of active cognitive remediation. Participants will complete 24 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
Receives: Behavioral: Active Cognitive Remediation; Behavioral: Online computer exercises; Behavioral: Strategy monitoring; Behavioral: Bridging strategies
Active Cognitive Remediation -Short-termActive comparatorParticipants in the short-term treatment will receive 12 weeks of active cognitive remediation (the standard length of time in the literature). Participants will complete 12 weeks of on-line computer exercises and participate in an on-line forum to facilitate strategy monitoring and bridging strategies.
Receives: Behavioral: Active Cognitive Remediation; Behavioral: Online computer exercises; Behavioral: Strategy monitoring; Behavioral: Bridging strategies
Cognitive Remediation ControlPlacebo comparatorParticipants in the comparison training group will login to the same training environment but the cognitive load will not adjust as it does in the experimental conditions. Participants in this group will complete 12 weeks of on-line computer exercises.
Receives: Behavioral: Cognitive Remediation Control; Behavioral: Online computer exercises; Behavioral: Strategy monitoring; Behavioral: Bridging strategies

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in composite neurocognition scores from the CNS Vitals Signs battery

    Neurocognitive Measure

    Measured: Participants will be tested at baseline, and assessed for changes at 12 weeks (post-intervention, intermediate intervention, or sham, respectively), and assessed for changes at 6 months post-intervention.

Secondary outcomes (8)
  1. Virtual Reality Functional Capacity Test

    Functional Capacity Measure

    Measured: Participants will be tested at baseline, and assessed for changes at 12 weeks (post-intervention, intermediate intervention, or sham, respectively), and assessed for changes at 6 months post-intervention.

  2. Composite neurocognition score from the CNS Vitals Signs battery

    Functional Capacity Measure

    Measured: Participants will be tested at baseline, and assessed for changes at 12 weeks (post-intervention, intermediate intervention, or sham, respectively), and assessed for changes at 6 months post-intervention.

  3. World Health Organization Quality of Life

    Everyday Functioning Measure

    Measured: Participants will be tested at baseline, and assessed for changes at 12 weeks (post-intervention, intermediate intervention, or sham, respectively), and assessed for changes at 6 months post-intervention.

  4. Bell-Lysaker Emotion Recognition Task

    Social Cognition Measure

    Measured: Participants will be tested at baseline, and assessed for changes at 12 weeks (post-intervention, intermediate intervention, or sham, respectively), and assessed for changes at 6 months post-intervention.

  5. Montgomery-Asberg Depression Rating Scale

    Mood symptom rating

    Measured: Participants will be tested at baseline, and assessed for changes at 12 weeks (post-intervention, intermediate intervention, or sham, respectively), and assessed for changes at 6 months post-intervention.

  6. Sheehan Disability Scale

    Self-reported quality of life

    Measured: Participants will be tested at baseline, and assessed for changes at 12 weeks (post-intervention, intermediate intervention, or sham, respectively), and assessed for changes at 6 months post-intervention.

  7. Lam Employment Absence and Productivity Scale

    Work outcomes

    Measured: Participants will be tested at baseline, and assessed for changes at 12 weeks (post-intervention, intermediate intervention, or sham, respectively), and assessed for changes at 6 months post-intervention.

  8. Need for Cognition Scale

    Self-reported need for cognitive demand in life

    Measured: Participants will be tested at baseline, and assessed for changes at 12 weeks (post-intervention, intermediate intervention, or sham, respectively), and assessed for changes at 6 months post-intervention.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Apr 2018
  2. Study startDec 2016
  3. Primary completionJul 2019 (estimated)
  4. Study completionJan 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
75 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03492203
Sponsor's protocol ID
PSYC-189-16
Acronym
RECORD
Status last verified
Aug 2018
First submitted
24 Dec 2016
Last updated
29 Aug 2018
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing Active Cognitive Remediation, Online computer exercises and Strategy monitoring in people with Major Depression, run by Queen's University at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Tammy L Vanrooy, BA Hons Law (613 533 6000 ext. 78478, tammy.vanrooy@queensu.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in composite neurocognition scores from the CNS Vitals Signs battery (time frame: Participants will be tested at baseline, and assessed for changes at 12 weeks (post-intervention, intermediate intervention, or sham, respectively), and assessed for changes at 6 months post-intervention.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Aug 2018; AzTrials last refreshed its copy on 27 Oct 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in